Maintenance risankizumab sustains induction response in patients with Crohn’s disease in a randomized Phase 3 trial

Subcutaneous risankizumab maintenance therapy results in durable improvement in clinical and endoscopic outcomes over one year in patients with moderately to severely active Crohn’s disease. Endpoint achievement tended to be achieved in a higher proportion of patients treated with 360mg risankizumab than 160mg risankizumab, and both doses were higher when compared to placebo.

This Phase 3 study by Ferrante, et al. assessed the maintenance of clinical, endoscopic and biomarker outcomes at 52 weeks of subcutaneous risankizumab treatment in patients with Crohn’s disease that had a 12-week intravenous risankizumab induction therapy.